ProCE Banner Activity

MCARH109, a GPCRC5D-Targeted CAR T-Cell Therapy, in Relapsed/Refractory MM: A Phase I First-in-Class Trial

Slideset Download
Conference Coverage
MCARH109 demonstrated a promising safety profile with high rates of clinical response in patients with heavily pretreated R/R MM, including those who relapsed post BCMA-targeted CAR T-cell therapy.

Released: December 20, 2021

Expiration: December 19, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation